Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial

Journal of Clinical Oncology

Volumn 22, Issue 1, 2004, Pages 157-165

  Meyers, Christina A ^a   Smith, Jennifer A ^b   Bezjak, Andrea ^b   Mehta, Minesh P ^b   Liebmann, James ^b   Illidge, Tim ^b   Kunkler, Ian ^b   Caudrelier, Jean Michel ^b   Eisenberg, Peter D ^b   Meerwaldt, Jacobus ^b   Siemers, Ross ^b   Carrie, Christian ^b   Gaspar, Laiirie E ^b   Curran, Walter ^b   Phan, See Chun ^b   Miller, Richard A ^b   Renschler, Markus F ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM TEXAPHYRIN;

ARTICLE; BRAIN FUNCTION; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MEMORY; MOTOR PERFORMANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; COGNITION DISORDERS; CRANIAL IRRADIATION; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEMORY DISORDERS; METALLOPORPHYRINS; MIDDLE AGED; MOTOR SKILLS; PSYCHOMETRICS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 3042787102     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.128     Document Type: Article

References (34)

1. Posner JB: Neurologic Complications of Cancer. Philadelphia, PA: F.A. Davis, 1995
2. Stuschke M, Eberhardt W, Pottgen C, et al: Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: Long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 17:2700-2709, 1999
3. Postmus PE, Haaxma-Reiche H, Smit EF, et al: Treatment of brain metastases of small-cell lung cancer: Comparing teniposide and teniposide with whole-brain radiotherapy-A phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 18:3400-3408, 2000
4. Robnett TJ, Machtay M, Stevenson JP, et al: Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol 19:1344-1349, 2001
5. Posner JB: Neurologic complication of cancer. Philadelphia, PA, F.A. Davis Company, 1995, pp 75-110
6. Wen PY, Loeffler JS: Management of brain metastases. Oncology 13:941-961, 1999
7. Posner JB: Management of brain metastases. Rev Neurol 148:477-487, 1992
8. Sawaya R, Bindal RK: Metastatic brain tumors, in Kaye AH, Laws ER (eds): Brain Tumors. Edinburgh, Scotland, Churchill Livingstone, 1995, p 923
9. Zimm S, Wampler GL, Stablein D, et al: Intracerebral metastases in solid tumor patients: Natural history and results of treatment. Cancer 48:384-394, 1981
10. Lagerwaard FJ, Levendag PC, Nowak PJ, et al: Identification of prognostic factors in patients with brain metastases: A review of 1292 patients. Int J Radiat Oncol Biol Phys 43:795-803, 1999
11. Nieder C, Nestle U, Motaref B, et al: Prognostic factors in brain metastases: Should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes? Int J Radiat Oncol Biol Phys 46:297-302, 2000
12. Gaspar L, Scott C, Rotman M, et al: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751, 1997
13. Borgelt B, Gelber R, Kramer S, et al: The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1-9, 1980
14. Murray KJ, Scott C, Greenberg HM, et al: A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 39:571-574, 1997
15. Chatani M, Teshima T, Hata K, et al: Prognostic factors in patients with brain metastases from lung carcinoma. Strahlenther Onkol 162:157-161, 1986
16. Chatani M, Matayoshi Y, Masaki N, et al: Radiation therapy for brain metastases from lung carcinoma: Prospective randomized trial according to the level of lactate dehydrogenase. Strahlenther Onkol 170:155-161, 1994
17. Harwood AR, Simson WJ: Radiation therapy of cerebral metastases: A randomized prospective clinical trial. Int J Radiat Oncol Biol Phys 2:1091-1094, 1977
18. Kurtz JM, Gelber R, Brady LW, et al: The palliation of brain metastases in a favorable patient population: A randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7:891-895, 1981
19. Komarnicky LT, Phillips TL, Martz K, et al: A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 20:53-58, 1991
20. Mehta MP, Shapiro WR, Glantz MJ, et al: Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20:3445-3453, 2002
21. Meyers CA, Boake C: Neurobehavioral disorders experienced by brain tumor patients: Rehabilitation strategies. Cancer Bull 45:362-364, 1993
22. Magda D, Lepp C, Gerasimchuk N, et al: Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 51:1025-1036, 2001
23. Miller RA, Woodburn K, Fan Q, et al: In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys 45:981-989, 1999
24. Xu S, Zakian K, Thaler H, et al: Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys 49:1381-1390, 2001
25. Viala J, Vanel D, Meingan P, et al: Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases. Radiology 212:755-759, 1999
26. Rosenthal DI, Nurenberg P, Becerra CR, et al: A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 5:739-745, 1999
27. Carde P, Timmerman R, Mehta MP, et al: Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 19:2074-2083, 2001
28. Mehta MM, Rodrigus P, Terhaard CHJ, et al: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole brain radiation therapy in brain metastases. J Clin Oncol 21:2529-2536, 2003
29. Benedict RHB, Schreiten D, Groninger L, et al: Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12:43-55, 1998
30. Benton AL, Hamsher KDS: Multilingual Aphasia Examination. Iowa City, IA, AJA Associates, 1989
31. Lezak MD. Neuropsychological Assessment (ed 3). New York, NY, Oxford University Press, 1995
32. Meyers CA, Hess KR, Yung WK, et al: Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18:646-650, 2000
33. Spreen O, Strauss E: A Compendium of Neuropsychological Tests (ed 2). New York, NY. Oxford University Press, 1998
34. Sperduto PW, Scott C, Andrews D, et al: Stereotactic radiosurgery with whole brain radiation therapy improves survival in patients with brain metastases: Report of Radiation Therapy Oncology Group Phase III Study 95-08 (ASTRO 2002). Int J Radiat Oncol Biol Phys 54:3, 2002 (abstr)